Study to Evaluate the Efficacy and Safety of Oral PF-06651600 and PF-06700841 in Subjects with Moderate to Severe Crohn’s Disease
A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Oral
PF-06651600 and PF-06700841 as Induction and Open Label Extension Treatment in Subjects With Moderate to Severe Crohn’s
Disease
Category & Conditions: Immune System Diseases and Conditions
Medicine: ritlecitinib (PF-06651600) / brepocitinib (PF-06700841)
ClinicalTrials.gov Identifier (NCT): NCT03395184
Protocol ID: B7981007 (PIZZICATO)
Open Plain Language Summary Result:
Click here